Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15578350.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Enfuvirtide is the first member of the fourth class of antiretroviral drugs to become available. We present a case report of a human immunodeficiency virus (HIV)-positive patient with mild renal impairment who developed severe renal impairment secondary to tenofovir therapy while receiving enfuvirtide. Because the patient's pharmacokinetic profile was not significantly altered, compared with that of HIV-infected patients with normal renal function, no dose modifications were required.
Medical subject headings
- HIV Fusion Inhibitors
- Kidney Diseases
- Peptide Fragments